Methods for identifying patients who will respond well to cancer treatment
作者： Jan Fagerberg
DOI:
关键词:
摘要: The present invention relates to methods for identifying patients who will respond well cancer treatment with a therapeutic regimen that comprises the use of histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents. also treating such comprising
lens.org 参考文章(74)
Baerbel Porstmann, Silke Lassmann, Martin Werner, Friedemann Krause, Thomas Walter, Manuela Poignee, Verena Lutz, Methods and compositions related to prediction of drug response ,(2004)
Y Ishibiki, M Kitajima, K Sakamoto, Y Tomiki, S Sakamoto, T Kamano, Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer. Journal of International Medical Research. ,vol. 31, pp. 181- 187 ,(2003) , 10.1177/147323000303100303
William LaRochelle, Henri Lichenstein, Xiaozhong Qian, Michael Jeffers, Evan Mills, Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies Cancer Research. ,vol. 67, pp. 691- 691 ,(2007)
Bernd Hentsch, Elke Martin, Sigrun Mink, The use of inhibitors of histone deacetylases in combination with compounds acting as nsaid for the therapy of human diseases ,(2006)
Robert B. Diasio, The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology. ,vol. 12, pp. 23- 27 ,(1998)
Richard Maziarz, Elliot Epner, Therapeutic drug combinations for treatment of b-cell malignancies ,(2008)
Yuji Minegishi, Akihiko Gemma, Masahiro Seike, Tsuneo Shimokawa, Akihiko Miyanaga, Shoji Kudoh, Tetsuya Okano, Kuniko Matsuda, Rintaro Noro, Kiyoko Kataoka, Michiya Nara, Hidehiko Kuribayashi, Akinobu Yoshimura, Hideaki Mizutani, SAHA (Histone deacetylase inhibitor) enhanced 5-FU sensitivity by downregulation of TS (Thymidylate Synthase) expression in lung cancer cells. Cancer Research. ,vol. 68, pp. 728- 728 ,(2008)
Anatoly Dritschilo, Mira O. Jung, Yali Kong, Milton L. Brown, Histone deacetylase inhibitors ,(2008)
D. James Koropatnick, Randall W. Berg, Mark D. Vincent, Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies ,(2003)
Henri Lichenstein, Nicholas Edwards, Jane Plumb, James Ritchie, Kamille Dumong Erichsen, Histone deacetylase (HDAC) inhibitors for the treatment of cancer ,(2014)